Patents Assigned to Hadasit
  • Patent number: 8680148
    Abstract: Methods for treating a bacterial infection by using a metallo-desferrioxamine complex.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: March 25, 2014
    Assignees: University of Washington, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: E. Peter Greenberg, Ehud Banin, Eyal Banin, Eduard Berenshtein, Mordechai Chevion
  • Publication number: 20140080782
    Abstract: A method of diagnosing pancreatic cancer in a subject is provided. The method comprising determining a level and/or activity of at least one saliva secreted marker in a saliva sample of the subject wherein an alteration in said marker with respect to an unaffected saliva sample is indicative of the pancreatic cancer.
    Type: Application
    Filed: December 13, 2011
    Publication date: March 20, 2014
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Aaron Palmon, Omer Deutsch, Doron Aframian, Oren Lahav
  • Patent number: 8666486
    Abstract: The present invention provides a device for iontophoretic delivery of a drug to on into a tissue, comprising an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. The present invention also provides a method for iontophorectivally administering drug to or into a tissue, comprising determination of a maximal allowed level of current density and preventing application of current density above the maximal allowed level.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: March 4, 2014
    Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Abraham J. Domb, Joseph Frucht-Pery, Mervyn Shapiro
  • Patent number: 8636411
    Abstract: A physical phantom reference to control for variability of computed tomography measurement results duplicates the density curve of blood perfusion of contrast material in a healthy aorta or large artery to normalize observed changes in healthy arterial blood perfusion when calculating the reduction in tumor blood perfusion between two examination times. In one embodiment, a plurality of compartments with different concentrations of contrast material corresponding to a density curve of blood perfusion of a healthy tissue are positioned-in a screening field of a CT machine so the CT machine images the compartments when it images the healthy tissue. In another embodiment, a pipe containing fluid receives an injection of contrast material from the injector when the injector injects the contrast material into the patient, the pipe having sections of varying diameter so the sections together correspond to a blood perfusion curve of the contrast material in a healthy tissue.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: January 28, 2014
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Jacob Sosna, Aviv Hirschenbain
  • Patent number: 8617561
    Abstract: An article of manufacture comprising packaging material and a pharmaceutical composition is disclosed, the article of manufacture being identified in print in or on the packaging material for treatment of an immunity-related disease in a subject in need thereof. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of modulating an interaction between a heparin-binding domain of a thrombospondin and a receptor of the heparin-binding domain.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: December 31, 2013
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Dror Mevorach, Alon Krispin, Yaniv Bledi, Michal Linial
  • Publication number: 20130331333
    Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
    Type: Application
    Filed: December 29, 2011
    Publication date: December 12, 2013
    Applicant: Hadasit Medical Research Services and Development Limited
    Inventor: Rachel Bar-Shavit
  • Patent number: 8597947
    Abstract: The present application discloses methods expanding SCs in an undifferentiated state, the methods comprising incubating undifferentiated SCs in suspension within a culture system comprising basic medium and knockout serum replacement (KOSR). The methods may also be applicable for selective spontaneous or directed differentiation of SCs into a selected population of somatic cells from a culture system of SCs in suspension, the method further comprising incubating said undifferentiated SCs in culture system that support respectively, spontaneous or directed differentiation of SCs into the selected population of somatic cells. The present application also discloses a culture system for expansion of stem cells (SCs) comprising a suspension of undifferentiated stem cells within basic medium and knockout serum replacement (KOSR). The methods and culture system of the invention may be used for large scale production of differentiated cells.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: December 3, 2013
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventor: Benjamin Reubinoff
  • Publication number: 20130314669
    Abstract: A method of diagnosis is disclosed. The method comprises using a display device for presenting a motion perception test to a subject and determining a subject response to the motion perception test. The response can be used for assessing presence or absence of demyelination and/or remyelination.
    Type: Application
    Filed: October 18, 2012
    Publication date: November 28, 2013
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Netta LEVIN, Noa Raz, Tamir Ben-Hur
  • Patent number: 8575307
    Abstract: The present invention provides peptides and peptide analogs capable of inhibiting the activity of protein kinase C. The invention discloses use of such peptides and analogs for preparation of pharmaceutical compositions and methods for prevention, delay, suppression or treatment of type 2 diabetes using such compositions.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: November 5, 2013
    Assignee: Hadasit Medical Research Services & Development Ltd.
    Inventors: Eleazar Shafrir, Ehud Ziv, Hadas Reuveni, Masha Niv
  • Publication number: 20130280218
    Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
    Type: Application
    Filed: September 27, 2011
    Publication date: October 24, 2013
    Applicant: Hadasit Medical Research Services & Development Limited
    Inventors: Sharona Cohen Evenram, Benjamin Reubinoff
  • Publication number: 20130245618
    Abstract: A highly controlled and precise system, device and method for tissue and cellular alteration and treatment below or at surfaces with a laser. The present invention is characterized by ultra low levels of collateral damage as defined by physiologically relevant tests that measure tissue viability. The operation of the present invention is based on spectrally confining the interaction between laser energy and a targeted tissue including an essential element for physiologically relevant tests for monitoring tissue viability.
    Type: Application
    Filed: May 6, 2013
    Publication date: September 19, 2013
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Eithan GALUN, Aaron Lewis, Evelyne Zeira, Alexandra Manevitch, Artium Khatchatouriants, Yitzchak Hemo
  • Patent number: 8535645
    Abstract: A particle including at least one aliphatic polymer having anti-microbially active quaternary ammonium groups chemically bound thereto, is provided. The particle may be used to inhibit populations of microorganisms and biofilms. Also provided are methods for the preparation of such particles and uses thereof for the inhibition of microorganisms.
    Type: Grant
    Filed: January 1, 2006
    Date of Patent: September 17, 2013
    Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Abraham J. Domb, Ervin Weiss, Nurit Beyth, Ira Farber, Michael Perez Davidi
  • Publication number: 20130202724
    Abstract: The invention provides methods and uses of different soybean extracts, for example, enzymatic, hexane, ethanol or aqueous soybean extracts and combinations thereof for the treatment of hepatic disorders, drug induced hepatic injury, the Metabolic Syndrome or an immune-related disorder in a subject in need thereof. The invention further provides pharmaceutical compositions, kits and methods thereof for treating and preventing hepatic disorders.
    Type: Application
    Filed: August 4, 2011
    Publication date: August 8, 2013
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Yaron Ilan
  • Patent number: 8461166
    Abstract: Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are further disclosed. The disclosed EGFR-TK inhibitors comprise a polyalkylene glycol moiety and/or a hydroxy-containing moiety and are characterized by improved solubility, biostability and bioavailability. Processes of preparing the disclosed EGFR-TK inhibitors and of radiolabeling same, via, for example, one-step radiosyntheses, are also disclosed.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: June 11, 2013
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Eyal Mishani, Samar Dissoki, Galith Abourbeh, Alexander Levitzki
  • Publication number: 20130137593
    Abstract: The present invention provides compositions, methods and kits for diagnosing cancer, specifically the diagnosis of colorectal cancer (CRC). More specifically, the invention provides simple assays, with high sensitivity and specificity for CRC, wherein a panel of microRNA (miRNA) are used as biomarkers.
    Type: Application
    Filed: April 14, 2011
    Publication date: May 30, 2013
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Aviram Nissan, Stella Mitrani Rosenbaum, Nadia Ilyayev, David Halle
  • Patent number: 8435791
    Abstract: A highly controlled and precise system, device and method for tissue and cellular alteration and treatment below or at surfaces with a laser. The present invention is characterized by ultra low levels of collateral damage as defined by physiologically relevant tests that measure tissue viability. The operation of the present invention is based on spectrally confining the interaction between laser energy and a targeted tissue including an essential element for physiologically relevant tests for monitoring tissue viability.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: May 7, 2013
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Eithan Galun, Aaron Lewis, Evelyne Zeira, Alexandra Manevitch, Artium Khatchatouriants, Yitzchak Hemo
  • Patent number: 8420092
    Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: April 16, 2013
    Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd.
    Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
  • Publication number: 20130084583
    Abstract: An isolated polypeptide comprising an amino acid sequence at least 70% homologous to SEQ ID NO: 4 and an isolated polynucleotide encoding same are disclosed. A polynucleotide comprising a nucleic acid sequence capable of specifically hybridizing to the isolated polynucleotide and an isolated antibody comprising an antigen recognition domain which specifically binds the isolated polypeptide are also disclosed. Pharmaceutical compositions, methods of diagnosing and treating comprising same are also disclosed.
    Type: Application
    Filed: November 27, 2012
    Publication date: April 4, 2013
    Applicants: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yissum Research Development Company of the H, Hadasit Medical Research Services and Developm
  • Publication number: 20130078238
    Abstract: A method or composition comprising an anti-CD3 immune molecule for treatment of hepatitis in a subject.
    Type: Application
    Filed: April 29, 2011
    Publication date: March 28, 2013
    Applicants: Hadasit Medical Research Services & Decvelopment Co. Ltd., NASVAX LTD.
    Inventors: Yaron Ilan, Ronald Ellis
  • Publication number: 20130078637
    Abstract: The present invention relates to genotypes associated with resistance to antipsychotic-induced parkinsonism and other extrapyramidal symptoms induced by antipsychotics, and use of said genotypes for assessment of patient populations. The methods and kits of the invention are based on identifying in a sample obtained from a subject, specific SNPs in the ZFPM2 and RGS2 genes.
    Type: Application
    Filed: May 26, 2011
    Publication date: March 28, 2013
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Bernard Lerer, Lior Greenbaum, Anna Alkelai